This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AbbVie Announces Market Availability Of New CREON® (pancrelipase) 36,000 Lipase-unit Capsules For Patients With Exocrine Pancreatic Insufficiency

NORTH CHICAGO, Ill., May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON ® (pancrelipase) Delayed-Release Capsules is commercially available in the United States.  The U.S. Food and Drug Administration (FDA) recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.  This new strength is the highest dose of pancreatic enzyme replacement therapy (PERT) currently available and approved by the FDA.

"Patients with EPI require replacement of enzymes to help them break down food into nutrients," said Dr. David C. Whitcomb, Chief, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh.  "Obtaining adequate lipase doses, however, often means taking a large number of capsules with each meal.  A higher lipase capsule dose is an option for some patients, and it may help reduce the number of capsules they take when compared to lower lipase products."

Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to produce enzymes that help in the digestion of food.  Patients living with cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions may develop EPI.  Symptoms of EPI may include steatorrhea (foul-smelling, greasy stools), gas, bloating, stomach pain, frequent bowel movements and weight loss.  Pancreatic enzymes work directly in the small intestines to help break down fats, proteins and carbohydrates, allowing the body to better digest the nutrients from food.

"We are pleased to be able to offer healthcare professionals increased choices in dosing options for their patients," said Maria Rivas, M.D., vice president, Global Medical Affairs, AbbVie.  "With the launch of this new CREON strength, healthcare professionals and patients now have access to the broadest range of dosage strengths in the PERT class."

UsesCREON ® (pancrelipase) Delayed-Release Capsules is a prescription medicine used to treat people who cannot digest food normally because their pancreas does not make enough enzymes due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.

Important Safety InformationCREON may increase the chance of having a rare bowel disorder called fibrosing colonopathy. The risk of having this condition may be reduced by following the dosing instructions given by the doctor.

CREON capsules or the contents of the capsules should not be crushed, chewed, or held in the mouth because this may cause mouth irritation. CREON should always be taken with a meal or snack and enough liquid to swallow CREON completely.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs